SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Bogdanoff who wrote (541)8/20/1997 12:34:00 PM
From: Henry Niman   of 2173
 
David, The press release did mention descreased insulin usage in Pramlintide patients and increased use in placebo patients for both type I and type II groups:

Here's what it said about Type I:
"The average daily dose of regular insulin
increased for patients on placebo and decreased for patients on pramlintide, each of which offset
measurable reductions in HbA1c levels attributable to pramlintide."

Here's what it said about type II:
"For example, compared to the 75 microgram dose arm, patients on placebo increased their
average daily dose of regular insulin by 12% (p = 0.0010)."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News